U.S. FDA approves Eagle’s generic version of Endo blood pressure drug (updated)

Eagle Pharmaceuticals

15/12/2021 19:54

(Adds background, share movement)
    Dec 15 (Reuters) - Eagle Pharmaceuticals Inc  EGRX.O  said
on Wednesday the U.S. health regulator approved its generic
version of Endo International's  ENDP.O  blood pressure drug,
Vasostrict, sending its shares to a more than one-month high.
    The U.S. Food and Drug Administration's approval comes just
months after a Delaware federal court ruled that Eagle's
proposed generic, vasopressin, did not infringe on patents held
by Endo subsidiary Par Pharmaceutical.
    Vasostrict brought in sales of more than $786 million last
year, making it the Endo's best-selling drug.
    Par sued Eagle in 2018 for seeking FDA approval of the
generic, alleging it infringed its patents. Eagle had denied
that, saying its formulation of the drug's active ingredient had
a pH value below the range covered by Par's patents.
    Eagle said on Wednesday it expects a 180-day marketing
exclusivity for vasopressin.  urn:newsml:reuters.com:*:nBw65KlLsa
    Shares of Eagle were up 8.5% at $50.6 in afternoon trading,
while those of Endo were down 2.3%.
    
    

 (Reporting by Dania Nadeem in Bengaluru; Editing by
Ramakrishnan M.)
 ((Dania.Nadeem@thomsonreuters.com;))